NASDAQ: $TECH
Bio-Techne Corporation, a leading global supplier of life science tools, reagents, and diagnostic products, has announced a major milestone: the Ella benchtop immunoassay platform has officially achieved CE-IVD marking and is now available for purchase throughout the European Union. This crucial certification opens the door for European clinical laboratories to adopt Ella’s industry-leading speed, ease of use, and superior reproducibility in their diagnostic workflows.
The Ella system is designed to tackle the time-consuming and variable nature of traditional immunoassays. As a compact, cartridge-based instrument, Ella dramatically simplifies the testing process, delivering accurate biomarker results in less than 90 minutes while demanding minimal hands-on time from laboratory staff. By automating complex manual steps, the platform significantly reduces operator-to-operator variability, ensuring high-quality, reproducible data suitable for stringent clinical applications.
Boosting Clinical Confidence and Efficiency
Will Geist, President of Bio-Techne’s Protein Sciences Segment, emphasized the significance of this achievement. “Ella’s CE-IVD certification marks a significant step forward in advancing precision diagnostics,” Geist stated. “It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes.”
With the CE-IVD status confirmed, European hospitals, clinical laboratories, and associated organizations can now confidently integrate Ella into their operations. This platform is now a validated resource for several critical activities, including:
- In-house Test Development: Laboratories can develop and validate their own diagnostic tests on a reliable, standardized platform.
- Clinical Trials: Ensuring consistent and dependable biomarker detection throughout the trial lifecycle.
- Translational Activities: Bridging research findings with patient-centric diagnostics more efficiently.
Furthermore, the platform supports diagnostic assay developers who seek to create clinical applications utilizing the Ella CE-IVD validated system. This move strengthens Bio-Techne’s overarching objective: to advance precision medicine by supplying dependable, standardized solutions for complex biomarker detection.
Leveraging the Power of Simple Plex™
The Ella platform is fully compatible with Simple Plex™ assays, which are powered by the globally recognized R&D Systems antibodies and proteins. While the Simple Plex assays currently remain designated for research use only, the expansive portfolio—boasting over 390 analytes across crucial areas like neuroscience, immunology, oncology, and cell and gene therapy—allows researchers to maintain exceptional data quality and consistency across diverse testing needs.
The integration of Simple Plex assays with the CE-IVD marked Ella instrument promises diagnostic developers a streamlined pathway to bringing high-performance, rapid immunoassays to the clinical forefront in Europe, ultimately supporting faster, more informed patient care.